Assembly Bio to launch four infectious disease trials in 2024
Assembly Bio has four candidates in its pipeline, one of which is being developed as part of a partnership with Gilead Sciences.
Assembly Bio has four candidates in its pipeline, one of which is being developed as part of a partnership with Gilead Sciences.
Originally operating as a subsidiary under BeiGene, Pi Health has become an independent company with a Series A raise.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Psychedelic treatments for mental health: Is there substance behind the hype?
AstraZeneca’s Evusheld fails to improve Covid outcomes in Phase III trial
Osivax kicks off broad spectrum coronavirus vaccine trial
SCOPE: FDA facilitates AI and ML use for clinical trials and drug development